Skip to search formSkip to main contentSkip to account menu

IDO Inhibitor NLG919

Known as: GDC-0919, NLG-919, NLG919 
An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Indoleamine-2,3-dioxygenase (IDO1) is well-recognized as an important target for immunotherapeutic intervention. Growing… 
2018
2018
Elevated tryptophan catabolism in many human tumors occurs due to activation of indoleamine 2,3-dioxygenase-1 (IDO1) or… 
2018
2018
Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options. Immune checkpoint inhibitors designed to revert… 
2016
2016
CRLX101, an investigational nanoparticle-drug conjugate (NDC) containing the payload camptothecin, is currently being clinically… 
2014
2014
Meeting abstracts Clinical Trial Registration Number: [NCT02048709][1] The enzyme Indoleamine 2,3-dioxygenase (IDO1) catalyzes… 
2014
2014
iTeos leverages the science of the LICR to target the metabolism of the tumor microenvironment and develops small-molecule… 
2010
2010
In opdracht van Rijkswaterstaat, dienst Zuid-Holland, heeft RAAP Archeologisch Adviesbureau in januari en mei 2010 een… 
2004
2004
50%igen U b e r s c h u g Th iony lch lo r id 4 mill bei 50 ~ uild d a n n 2 S td bei R a u m t e m p e r a t u r . Das h i e r d…